The Latest Cardiac and Vascular News
LEXEO completes license of all intellectual property rights and pre-clinical data associated with Adverum Biotechnologies’ investigational Friedreich’s ataxia program Pre-clinical research licensed from academic partners and data from Adverum’s program now consolidated to support the advancement of LX2006; Phase 1 clinical trial expected to initiate in 2021 NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) — LEXEO […]
TEL AVIV, Israel, March 1, 2021 /PRNewswire/ — Vascular Grafts Solutions (VGS) Ltd. announced today receipt of marketing clearance from the Food and Drug Administration (FDA) for the VIOLA™, a new device for clampless proximal anastomosis in coronary artery bypass grafting (CABG) Neurocognitive dysfunction remains the most devastating perioperative complication of CABG […]
Successful use of the Satera™ Ablation System aims to improve chronic heart failure NEW YORK, March 1, 2021 /PRNewswire/ — Axon Therapies, a Coridea portfolio company focused on addressing a root cause of heart failure, today announced the treatment of the first patient in the randomized, controlled REBALANCE-HF IDE feasibility trial. The trial […]
The First Gene Based Project to be conducted in the Texas Rio Grande Valley EDINBURG, Texas–(BUSINESS WIRE)–Can a medical tool predict the risk of certain medications based on a patient’s genetics, and, if so, could this information lead to doctors customizing a patient’s drug therapy? The tool being studied at […]
Silence Therapeutics and Mallinckrodt Initiate Work on Third Target as Part of Ongoing RNAi Research Collaboration for Complement-Mediated Diseases Silence to receive $2 million research milestone payment Silence is also eligible to receive up to $2 billion in total milestone payments across all three targets and tiered double-digit royalties on […]
Enrollment with advanced generation device for complete cerebral protection nearing halfway mark in clinical study in Germany and Poland AACHEN, Germany–(BUSINESS WIRE)–Protembis GmbH, a privately held emerging medical device company, announced today the successful completion of 20 clinical cases in its European regulatory study of the ProtEmbo® Cerebral Protection System. The […]
SCHAFFHAUSEN, Switzerland, Feb. 24, 2021 /PRNewswire/ — Occlutech, a privately-held company, announced today the completion of patient enrolment in its pilot study to assess safety and efficacy of the novel Atrial Flow Regulator (AFR) in heart failure (HF) patients (PRELIEVE trial). PRELIEVE is a prospective, multicenter, open-label, non-randomized pilot study that evaluates the […]
Intramyocardial injection of Lomecel-B well-tolerated, with no major cardiac events, and no serious adverse events related to Lomecel-B reported Full results of the Phase 1 clinical trial expected to be released in Q2 2021 Phase 2 trial expected to commence in Q3 2021 MIAMI, Feb. 24, 2021 (GLOBE NEWSWIRE) — […]
The world’s smallest pediatric treatments, developed by Abbott, meet the needs of the most vulnerable patients: babies and children born with congenital heart defects Approval includes use of a pediatric mechanical heart valve and the first minimally invasive device to treat premature and newborn babies with an opening in the […]
NMPA Clears the Way for Impulse Dynamics to Deliver Hope for Heart Failure Population MARLTON, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) — Impulse Dynamics, a company dedicated to improving the lives of people with heart failure (HF), today announced that the National Medical Products Administration (NMPA) approved the application for […]
